Each company spent more than 15% of their revenue on research.
These 10 medtech companies have spent the largest share of their annual sales on R&D, according to Medical Design & Outsourcing‘s annual Big 100. Here’s a look at the research-related news each medical device developer accomplished in 2022.
Each year, Medical Design & Outsourcing ranks the world’s largest 100 medical device companies based on annual revenue.
As an indicator of how well the industry is performing, we also compile and calculate R&D spending figures. Our latest analysis found medtech sales set a new record high and R&D spending accelerated despite economic headwinds.
Annual R&D spending at large medical device companies grew more than $1.1 billion — or 5.1% — to $23.4 billion, according to the most recent data available in our Big 100 analysis.
Five companies in the Big 100 spent more than 20% of their revenue on R&D, and the top 10 spent more than 15%. Click through the tabs below to see how much money each company reported spending on research and the news that came out of that spending.
10. Abiomed
R&D spending: $163,403,000 Percentage of revenue: 15.8% 2022 Big 100 rank: 68
9. Edwards Lifesciences
R&D spending: $903,100,000 Percentage of revenue: 17.3% 2022 Big 100 rank: 24
8. AtriCure
R&D spending: $48,506,000 Percentage of revenue: 17.7% 2022 Big 100 rank: 97
7. LivaNova
R&D spending: $183,414,000 Percentage of revenue: 17.7% 2022 Big 100 rank: 67
6. Inari Medical
R&D spending: $51,018,000 Percentage of revenue: 18.4% 2022 Big 100 rank: 96
5. Dexcom
R&D spending: $517,100,000 Percentage of revenue: 21.1% 2022 Big 100 rank: 45
4. Shockwave Medical
R&D spending: $50,544,000 Percentage of revenue: 21.3% 2022 Big 100 rank: 99
3. Glaukos
R&D spending: $100,999,000 Percentage of revenue: 34.4% 2022 Big 100 rank: 95
2. Novocure
R&D spending: $201,303,000 Percentage of revenue: 37.6% 2022 Big 100 rank: 84
1. MicroPort
R&D spending: $297,800,000 Percentage of revenue: 38.2% 2022 Big 100 rank: 77
تعليقات